NASDAQ: HRTXHeron Therapeutics Inc Stock Ownership - Who owns Heron Therapeutics?
Insider buying vs selling
Have Heron Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Mark Earl Hensley | COO | 2026-08-06 | 8,888 | $0.50 | $4.44kSell |
| William P. Forbes | EVP;CXO | 2026-07-31 | 3,326 | $0.50 | $1.66kSell |
| Ira Duarte | CFO;EVP | 2026-07-31 | 3,326 | $0.50 | $1.66kSell |
| William P. Forbes | EVP;CXO | 2026-07-30 | 3,348 | $0.50 | $1.67kSell |
| Ira Duarte | CFO;EVP | 2026-07-30 | 3,850 | $0.50 | $1.93kSell |
| William P. Forbes | EVP;CXO | 2026-07-19 | 1,101 | $0.47 | $517.47Sell |
| Ira Duarte | CFO;EVP | 2026-07-19 | 1,101 | $0.47 | $517.47Sell |
| Ira Duarte | EVP Chief Financial Officer | 2026-06-16 | 3,555 | $0.38 | $1.35kSell |
HRTX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when HRTX insiders and whales buy or sell their stock.
HRTX Shareholders
What type of owners hold Heron Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Spch LLC | 20.11% | 38,174,476 | $11.80M | Insider |
| Rubric Capital Management LP | 15.83% | 30,046,828 | $9.28M | Insider |
| Perceptive Advisors LLC | 14.05% | 26,666,667 | $8.24M | Insider |
| Adam Morgan | 4.68% | 8,877,027 | $2.74M | Insider |
| Baker Brothers Life Sciences Capital GP LLC | 2.77% | 5,266,568 | $1.63M | Insider |
| Velan Capital Investment Management LP | 2.37% | 4,500,000 | $1.39M | Insider |
| Kevin C. Tang | 2.11% | 4,014,771 | $1.24M | Insider |
| Savitr Capital LLC | 0.90% | 1,712,366 | $529.12k | Insider |
| Baker Biotech Capital GP LLC | 0.75% | 1,432,692 | $442.70k | Insider |
| Craig A. Collard | 0.45% | 856,492 | $264.66k | Insider |
HRTX vs Biotech Stocks
Heron Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.